Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
4 "Zhen-Yu He"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Impact of 21-Gene Recurrence Score on Chemotherapy Decision in Invasive Ductal Carcinoma of Breast with Nodal Micrometastases
Wei-Rong Chen, Jia-Peng Deng, Jun Wang, Jia-Yuan Sun, Zhen-Yu He, San-Gang Wu
Cancer Res Treat. 2019;51(4):1437-1448.   Published online March 4, 2019
DOI: https://doi.org/10.4143/crt.2018.611
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study was to investigate the effect of 21-gene recurrence score (RS) on predicting prognosis and chemotherapy decision in node micrometastases (N1mi) breast invasive ductal carcinoma (IDC).
Methods
Patients with stage T1-2N1mi and estrogen receptor-positive IDC diagnosed between 2004 and 2015 were included. The associations of 21-gene RS with breast cancer-specific survival (BCSS), chemotherapy decision, and benefit of chemotherapy were analyzed.
Results
We identified 4,758 patients including 1,403 patients (29.5%) treated with adjuvant chemotherapy. In the traditional RS cutoffs, 2,831 (59.5%), 1,634 (34.3%), and 293 (6.2%) patients were in the low-, intermediate-, and high-risk RS groups, respectively. In 3,853 patients with human epidermal growth factor receptor-2 (HER2) status available, most patients were HER2-negative disease (98.3%). A higher RS was independently related to chemotherapy receipt, and 14.0%, 47.7%, and 77.8% of patients in the low-, intermediate-, and high-risk RS groups received chemotherapy, respectively. The multivariate analysis indicated that a higher RS was related to worse BCSS (p < 0.001). The 5-year BCSS rates were 99.3%, 97.4%, and 91.9% in patients with low-, intermediate-, and high-risk RS groups, respectively (p < 0.001). However, chemotherapy receipt did not correlate with better BCSS in low-, intermediate-, or high-risk RS groups. There were similar trends using Trial Assigning Individualized Options for Treatment RS cutoffs.
Conclusion
The 21-gene RS does predict outcome and impact on chemotherapy decision of N1mi breast IDC. Large cohort and long-term outcomes studies are needed to identify the effects of chemotherapy in N1mi patients by different 21-gene RS groups.

Citations

Citations to this article as recorded by  
  • 21-gene recurrence score predictive of the benefit of postoperative radiotherapy after breast-conserving surgery for elderly patients with T1N0 and luminal breast cancer
    Run-Jie Wang, Hai-Ying Liu, Lin-Feng Guo, De Yu, San-Gang Wu
    Breast Cancer.2024; 31(6): 1156.     CrossRef
  • Evaluation of adjuvant therapy for T1-2N1miM0 breast cancer without further axillary lymph node dissection
    Baiyu Li, Jianbo Liu, Guangyin Wu, Qingyao Zhu, Shundong Cang
    Frontiers in Surgery.2023;[Epub]     CrossRef
  • Effectiveness of post-mastectomy adjuvant chemotherapy for the treatment of patients with prognostic stage IB breast cancer: A SEER-based study
    HongMei Wang, Yi Peng, Jianbin Wu, ZhuangWei Chen, HuaLe Zhang
    Asian Journal of Surgery.2023; 46(9): 3634.     CrossRef
  • Comparison of 21-gene assay and St.Gallen International Expert Consensus in the treatment decision for patients with early invasive breast cancers
    Ming Luo, Fu Li, Ka Su, Huiming Yuan, Jian Zeng
    Cancer Biology & Therapy.2020; 21(2): 108.     CrossRef
  • Oncotype DX Breast Recurrence Score®: A Review of its Use in Early-Stage Breast Cancer
    Yahiya Y. Syed
    Molecular Diagnosis & Therapy.2020; 24(5): 621.     CrossRef
  • 6,897 View
  • 140 Download
  • 5 Web of Science
  • 5 Crossref
Close layer
KIF11 Functions as an Oncogene and Is Associated with Poor Outcomes from Breast Cancer
Juan Zhou, Wei-Rong Chen, Li-Chao Yang, Jun Wang, Jia-Yuan Sun, Wen-Wen Zhang, Zhen-Yu He, San-Gang Wu
Cancer Res Treat. 2019;51(3):1207-1221.   Published online December 27, 2018
DOI: https://doi.org/10.4143/crt.2018.460
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The study aimed to search and identify genes that were differentially expressed in breast cancer, and their roles in cancer growth and progression.
Materials and Methods
The Gene Expression Omnibus (Oncomine) and The Cancer Genome Atlas databases (https://cancergenome.nih.gov/) were screened for genes that were expressed differentially in breast cancer and were closely related to a poor prognosis. Gene expressions were verified by quantitative real-time polymerase chain reaction, and genes were knocked down by a lentivirus-based system. Cell growth and motility were evaluated and in vivo nude mice were used to confirm the in vitro roles of genes. Markers of epithelial-to-mesenchymal transition and the associations of KIF11 with the classical cancer signaling pathways were detected by Western blot.
Results
A series of genes expressed differentially in patients with breast cancer. The prognosis associated with high KIF11 expression was poor, and the expression of KIF11 increased significantly in high stage and malignant tumor cells. Inhibiting KIF11 expression in lentivirus-suppressed cells revealed that KIF11 inhibition significantly reduced cell viability and colony formation, inhibited migration and invasion, but promoted apoptosis. The sizes and weights of KIF11-inhibited tumors in nude mice were significantly lower than in the negative controls. Western blot showed that E-cadherin in breast cancer was significantly upregulated in KIF-inhibited cells and tumor tissues, whereas N-cadherin and vimentin were significantly downregulated. BT549 and MDA231 cells with KIF11 knockdown exhibited decreased ERK, AMPK, AKT, and CREB phosphorylation.
Conclusion
KIF11 acts as a potential oncogene that regulates the development and progression of breast cancer.

Citations

Citations to this article as recorded by  
  • HELLS Knockdown Inhibits the Malignant Progression of Lung Adenocarcinoma Via Blocking Akt/CREB Pathway by Downregulating KIF11
    Gang Yang, Jinsong Fu, Jiawei Wang, Mei Ding
    Molecular Biotechnology.2025; 67(2): 548.     CrossRef
  • Identification of potential biomarkers for 2022 Mpox virus infection: a transcriptomic network analysis and machine learning approach
    Joy Prokash Debnath, Kabir Hossen, Sabrina Bintay Sayed, Md. Sayeam Khandaker, Preonath Chondrow Dev, Saifuddin Sarker, Tanvir Hossain
    Scientific Reports.2025;[Epub]     CrossRef
  • GPSM1 interacts and cooperates with MMP19 to promote proliferation and EMT in colorectal cancer cells
    Lu Wang, Na Li, Yang Chen, Yehua Qiao, Yaolin Song, Xiangyan Zhang, Han Zhao, Wenwen Ran, Guangqi Li, Xiaoming Xing
    Biochimica et Biophysica Acta (BBA) - Molecular Cell Research.2025; 1872(3): 119903.     CrossRef
  • Identification and validation of the important role of KIF11 in the development and progression of endometrial cancer
    Biying Wang, Lunmin Bao, Xiaoduo Li, Guang Sun, Wu Yang, Nanzi Xie, Ling Lei, Wei Chen, Hailong Zhang, Man Chen, Xing Zhao, Xiufang Wan, Rui Yuan, Hongmei Jiang
    Journal of Translational Medicine.2025;[Epub]     CrossRef
  • Integrative analysis of T cell-mediated tumor killing-related genes reveals KIF11 as a novel therapeutic target in esophageal squamous cell carcinoma
    Xinxin Cheng, Huihui Zhao, Zhangwang Li, Liping Yan, Qingjie Min, Qingnan Wu, Qimin Zhan
    Journal of Translational Medicine.2025;[Epub]     CrossRef
  • KIF11 and KIF14 Are a Novel Potential Prognostic Biomarker in Patients with Endometrioid Carcinoma
    Paulina Antosik, Justyna Durślewicz, Marta Smolińska-Świtała, Jonasz Podemski, Edyta Podemska, Izabela Neska-Długosz, Jakub Jóźwicki, Dariusz Grzanka
    Cancers.2025; 17(5): 804.     CrossRef
  • Identification of Hub Genes and Potential Drugs in Neurofibromatosis 1: An Integrated Bioinformatics Analysis
    Zoha Adnan, Muhammad Asif Rasheed, Sami Ullah Khan, Areeba Irfan, Fuad A. Awwad, Emad A. A. Ismail, M. Ijaz Khan, Nargiza Kamolova
    Journal of Computational Biophysics and Chemistry.2025; 24(03): 359.     CrossRef
  • Targeting Eg5 using Arry520 combats gastric cancer by inducing monopolar spindles
    Na He, Xinyuan Wei, Ruofei Sun, Gengyuan Zhang, Jie Zhao, Xiangyan Jiang, Bo Long, Zeyuan Yu, Wengui Shi, Zuoyi Jiao
    Gene.2025; 955: 149458.     CrossRef
  • The role of kinesin family members in hepatobiliary carcinomas: from bench to bedside
    Kai Zhao, Xiangyu Li, Yunxiang Feng, Jianming Wang, Wei Yao
    Biomarker Research.2024;[Epub]     CrossRef
  • Mitotic Functions and Characters of KIF11 in Cancers
    Wanting Gao, Junjie Lu, Zitao Yang, Enmin Li, Yufei Cao, Lei Xie
    Biomolecules.2024; 14(4): 386.     CrossRef
  • Kinesin 26B modulates M2 polarization of macrophage by activating cancer-associated fibroblasts to aggravate gastric cancer occurrence and metastasis
    Lian-Meng Huang, Ming-Jin Zhang
    World Journal of Gastroenterology.2024; 30(20): 2689.     CrossRef
  • Di-(2-ethylhexyl) phthalate promotes benign prostatic hyperplasia through KIF11-Wnt/β-catenin signaling pathway
    Pan Song, Dong Lv, Luchen Yang, Jing Zhou, Xin Yan, Zhenghuan Liu, Kai Ma, Yunfei Yu, Xiaoyang Liu, Qiang Dong
    Ecotoxicology and Environmental Safety.2024; 281: 116602.     CrossRef
  • Transcriptomic profiles‐based approach to decode the role of miR‐122 in triple negative breast cancer
    Mauricio Flores Fortis, Isidro X. Perez Añorve, Oscar del Moral Hernandez, Nicolas Villegas, Elena Arechaga Ocampo
    Genes, Chromosomes and Cancer.2023; 62(7): 392.     CrossRef
  • ASPM promotes migration and invasion of anaplastic thyroid carcinoma by stabilizing KIF11
    Qilu Fang, Qinglin Li, Yajun Qi, Zongfu Pan, Tingting Feng, Wenxiu Xin
    Cell Biology International.2023; 47(7): 1209.     CrossRef
  • Effect of KIF15 as a promoter role in the progression of osteosarcoma based on TCGA database
    Jin Qian, Laicheng Zou, Xiao Han, Zhen Zhang, Qing Qiu, Liulong Zhu, Zhenyu Bian
    Soft Computing.2023;[Epub]     CrossRef
  • KIF11 serves as a cell cycle mediator in childhood acute lymphoblastic leukemia
    Liwen Zhu, Chuqin Chen, Meiyun Kang, Xiaopeng Ma, Xiaoyan Sun, Yao Xue, Yongjun Fang
    Journal of Cancer Research and Clinical Oncology.2023; 149(17): 15609.     CrossRef
  • Protooncogenic Role of ARHGAP11A and ARHGAP11B in Invasive Ductal Carcinoma: Two Promising Breast Cancer Biomarkers
    Y. Naeimzadeh, S. Ilbeigi, H. Dastsooz, M. Rafiee Monjezi, Y. Mansoori, S. M. B. Tabei, Yuan Li
    BioMed Research International.2023;[Epub]     CrossRef
  • Upregulation of KIF11 in TP53 Mutant Glioma Promotes Tumor Stemness and Drug Resistance
    Bin Liu, Gang Zhang, Shukun Cui, Guoliang Du
    Cellular and Molecular Neurobiology.2022; 42(5): 1477.     CrossRef
  • High KIF11 expression is associated with poor outcome of NSCLC
    Junhui Liu, Yubin Tian, Lei Yi, Zhaojia Gao, Ming Lou, Kai Yuan
    Tumori Journal.2022; 108(1): 40.     CrossRef
  • Negative Modulation of the Angiogenic Cascade Induced by Allosteric Kinesin Eg5 Inhibitors in a Gastric Adenocarcinoma In Vitro Model
    Alessia Ricci, Marialucia Gallorini, Donatella Del Bufalo, Amelia Cataldi, Ilaria D’Agostino, Simone Carradori, Susi Zara
    Molecules.2022; 27(3): 957.     CrossRef
  • Oncological drug discovery: AI meets structure-based computational research
    Marina Gorostiola González, Antonius P.A. Janssen, Adriaan P. IJzerman, Laura H. Heitman, Gerard J.P. van Westen
    Drug Discovery Today.2022; 27(6): 1661.     CrossRef
  • Targeting kinesin family member 21B by miR-132-3p represses cell proliferation, migration and invasion in gastric cancer
    Bingtian Liu, Ling Qiang, Bingxin Guan, Zhipeng Ji
    Bioengineered.2022; 13(4): 9006.     CrossRef
  • KIF11 manipulates SREBP2‐dependent mevalonate cross talk to promote tumor progression in pancreatic ductal adenocarcinoma
    Xiang Gu, Qunshan Zhu, Guangyu Tian, Wenbo Song, Tao Wang, Ali Wang, Xiaojun Chen, Songbing Qin
    Cancer Medicine.2022; 11(17): 3282.     CrossRef
  • KIF11 Is a Promising Therapeutic Target for Thyroid Cancer Treatment
    Yue Han, Jing Chen, Dianjun Wei, Baoxi Wang, Shakeel Ahmad
    Computational and Mathematical Methods in Medicine.2022; 2022: 1.     CrossRef
  • Kinesin Eg5 Selective Inhibition by Newly Synthesized Molecules as an Alternative Approach to Counteract Breast Cancer Progression: An In Vitro Study
    Alessia Ricci, Amelia Cataldi, Simone Carradori, Susi Zara
    Biology.2022; 11(10): 1450.     CrossRef
  • Comprehensive analysis of prognostic value, relationship to cell cycle, immune infiltration and m6A modification of ZSCAN20 in hepatocellular carcinoma
    Fang Jiayu, Yike Jiang, Xuanrui Zhou, Minqin Zhou, Jingying Pan, Yun Ke, Jing Zhen, Da Huang, Weifan Jiang
    Aging.2022;[Epub]     CrossRef
  • Integrative analysis of transcriptional profile reveals LINC00052 as a suppressor of breast cancer cell migration
    Jose Manuel Sanchez-Lopez, Edna Ayerim Mandujano-Tinoco, Alfredo Garcia-Venzor, Laura Fatima Lozada-Rodriguez, Cecilia Zampedri, Salvador Uribe-Carvajal, Jorge Melendez-Zajgla, Vilma Maldonado, Floria Lizarraga
    Cancer Biomarkers.2021; 30(4): 365.     CrossRef
  • Identification of the Hub Genes Associated with the Prognosis of Ovarian Cancer Patients via Integrated Bioinformatics Analysis and Experimental Validation
    Yuzi Zhao, Jie Pi, Lihua Liu, Wenjie Yan, Shufang Ma, Li Hong
    Cancer Management and Research.2021; Volume 13: 707.     CrossRef
  • Overexpression of EZH2/NSD2 Histone Methyltransferase Axis Predicts Poor Prognosis and Accelerates Tumor Progression in Triple-Negative Breast Cancer
    Bo Gao, Xiumin Liu, Zhengjin Li, Lixian Zhao, Yun Pan
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • KIF11 inhibitors filanesib and ispinesib inhibit meningioma growth in vitro and in vivo
    Gerhard Jungwirth, Tao Yu, Junguo Cao, Montadar Alaa Eddine, Mahmoud Moustafa, Rolf Warta, Juergen Debus, Andreas Unterberg, Amir Abdollahi, Christel Herold-Mende
    Cancer Letters.2021; 506: 1.     CrossRef
  • KIF11 Serves as an Independent Prognostic Factor and Therapeutic Target for Patients With Lung Adenocarcinoma
    Zhaodong Li, Bingxin Yu, Fangyuan Qi, Fan Li
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Dauricine inhibits human pancreatic carcinoma cell proliferation through regulating miRNAs
    Ling Jiang, Tianzhu Guo, Ying Jiang, Ping Liu, Yun Bai
    Molecular Omics.2021; 17(4): 630.     CrossRef
  • ASPM combined with KIF11 promotes the malignant progression of hepatocellular carcinoma via the Wnt/β‑catenin signaling pathway
    Bin Wu, Chunyang Hu, Lianbao Kong
    Experimental and Therapeutic Medicine.2021;[Epub]     CrossRef
  • Screening and predicted value of potential biomarkers for breast cancer using bioinformatics analysis
    Xiaoyu Zeng, Gaoli Shi, Qiankun He, Pingping Zhu
    Scientific Reports.2021;[Epub]     CrossRef
  • Screening and identification of hub genes in bladder cancer by bioinformatics analysis and KIF11 is a potential prognostic biomarker
    Xiao-Cong Mo, Zi-Tong Zhang, Meng-Jia Song, Zi-Qi Zhou, Jian-Xiong Zeng, Yu-Fei Du, Feng-Ze Sun, Jie-Ying Yang, Jun-Yi He, Yue Huang, Jian-Chuan Xia, De-Sheng Weng
    Oncology Letters.2021;[Epub]     CrossRef
  • Kinesin superfamily proteins: roles in osteosarcoma
    Yao Lu, Tao Song, Xue Xue, Gaolu Cao, Panpan Huang
    Frontiers in Bioscience-Landmark.2021;[Epub]     CrossRef
  • KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors
    Ernest Terribas, Marco Fernández, Helena Mazuelas, Juana Fernández-Rodríguez, Josep Biayna, Ignacio Blanco, Gabriela Bernal, Irma Ramos-Oliver, Craig Thomas, Rajiv Guha, Xiaohu Zhang, Bernat Gel, Cleofé Romagosa, Marc Ferrer, Conxi Lázaro, Eduard Serra
    Neuro-Oncology Advances.2020; 2(Supplement): i62.     CrossRef
  • Kinesin family member 11 is a potential therapeutic target and is suppressed by microRNA‐30a in breast cancer
    Benfang Wang, Jianjiang Yu, Zhenjiang Sun, Frank Luh, Dandan Lin, Ying Shen, Ting Wang, Qi Zhang, Xiyong Liu
    Molecular Carcinogenesis.2020; 59(8): 908.     CrossRef
  • Development and validation of a five‐gene model to predict postoperative brain metastasis in operable lung adenocarcinoma
    Fangqiu Fu, Yang Zhang, Zhendong Gao, Yue Zhao, Zhexu Wen, Han Han, Yuan Li, Haiquan Chen
    International Journal of Cancer.2020; 147(2): 584.     CrossRef
  • GSG2 (Haspin) promotes development and progression of bladder cancer through targeting KIF15 (Kinase-12)
    Yuhao Chen, Dian Fu, Hai Zhao, Wen Cheng, Feng Xu
    Aging.2020; 12(10): 8858.     CrossRef
  • Identification of Metastasis-Associated Biomarkers in Synovial Sarcoma Using Bioinformatics Analysis
    Yan Song, Xiaoli Liu, Fang Wang, Xiaoying Wang, Guanghui Cheng, Changliang Peng
    Frontiers in Genetics.2020;[Epub]     CrossRef
  • Identification of Hub Genes in Anaplastic Thyroid Carcinoma: Evidence From Bioinformatics Analysis
    Liqi Li, Mingjie Zhu, Hu Huang, Junqiang Wu, Dong Meng
    Technology in Cancer Research & Treatment.2020;[Epub]     CrossRef
  • Exploration and validation of a novel prognostic signature based on comprehensive bioinformatics analysis in hepatocellular carcinoma
    Xiaofei Wang, Jie Qiao, Rongqi Wang
    Bioscience Reports.2020;[Epub]     CrossRef
  • Identification of candidate biomarkers correlated with the pathogenesis and prognosis of breast cancer via integrated bioinformatics analysis
    Shuyu Liu, Xinkui Liu, Jiarui Wu, Wei Zhou, Mengwei Ni, Ziqi Meng, Shanshan Jia, Jingyuan Zhang, Siyu Guo, Shan Lu, Yingfei Li
    Medicine.2020; 99(49): e23153.     CrossRef
  • Identification of Potential Hub Genes Related to Diagnosis and Prognosis of Hepatitis B Virus‐Related Hepatocellular Carcinoma via Integrated Bioinformatics Analysis
    Yuqin Tang, Yongqiang Zhang, Xun Hu, Nagarajan Raju
    BioMed Research International.2020;[Epub]     CrossRef
  • KIF14 and KIF23 Promote Cell Proliferation and Chemoresistance in HCC Cells, and Predict Worse Prognosis of Patients with HCC
    Chunxia Cheng, Xingxing Wu, Yu Shen, Quanxi Li
    Cancer Management and Research.2020; Volume 12: 13241.     CrossRef
  • Identification of KIF11 as a Novel Target in Meningioma
    Gerhard Jungwirth, Tao Yu, Mahmoud Moustafa, Carmen Rapp, Rolf Warta, Christine Jungk, Felix Sahm, Steffen Dettling, Klaus Zweckberger, Katrin Lamszus, Christian Senft, Mario Loehr, Almuth F. Keßler, Ralf Ketter, Manfred Westphal, Juergen Debus, Andreas v
    Cancers.2019; 11(4): 545.     CrossRef
  • Knockdown of Kinase Family 15 Inhibits Cancer Cell Proliferation In vitro and its Clinical Relevance in Triple-Negative Breast Cancer
    Jiayu Sheng, Xiaohong Xue, Ke Jiang
    Current Molecular Medicine.2019; 19(2): 147.     CrossRef
  • 11,399 View
  • 336 Download
  • 55 Web of Science
  • 48 Crossref
Close layer
Using the Lymph Node Ratio to Evaluate the Prognosis of Stage II/III Breast Cancer Patients Who Received Neoadjuvant Chemotherapy and Mastectomy
San-Gang Wu, Qun Li, Juan Zhou, Jia-Yuan Sun, Feng-Yan Li, Qin Lin, Huan-Xin Lin, Xun-Xing Gaun, Zhen-Yu He
Cancer Res Treat. 2015;47(4):757-764.   Published online December 8, 2014
DOI: https://doi.org/10.4143/crt.2014.039
AbstractAbstract PDFPubReaderePub
Purpose
This study was conducted to investigate the prognostic value of lymph node ratio (LNR) in stage II/III breast cancer patients who undergo mastectomy after neoadjuvant chemotherapy.
Materials and Methods
Clinical and pathological data describing stage II/III breast cancer patients were included in this retrospective study. The primary outcomes were locoregional recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS).
Results
Among 277 patients, there were 43 ypN0, 64 ypN1, 89 ypN2, and 81 ypN3 cases. Additionally, there were 43, 57, 92 and 85 cases in the LNR 0, 0.01-0.20, 0.21-0.65, and > 0.65 groups, respectively. The median follow-up was 49.5 months. Univariate analysis showed that both ypN stage and LNR were prognostic factors of LRFS, DMFS, DFS, and OS (p < 0.05). Multivariate analysis showed that LNR was an independent prognostic factor of LRFS, DMFS, DFS, and OS (p < 0.05), while ypN stage had no effect on prognosis (p > 0.05).
Conclusion
The integrated use of LNR and ypN may be suitable for evaluation the prognosis of stage II/III breast cancer patients who undergo mastectomy after neoadjuvant chemotherapy.

Citations

Citations to this article as recorded by  
  • Prognosis and influencing factors of ER-positive, HER2-low breast cancer patients with residual disease after neoadjuvant chemotherapy: a retrospective study
    Lingfeng Tang, Linshan Jiang, Xiujie Shu, Yudi Jin, Haochen Yu, Shengchun Liu
    Scientific Reports.2024;[Epub]     CrossRef
  • Prognostic disparities in young patients based on breast cancer subtype: A population-based study from the SEER database
    Bing Chen, Xiaojuan Zhang, Yi Liu, Chuandong Wang
    Medicine.2023; 102(13): e33416.     CrossRef
  • The Effect of Lymph Node Harvest on Prognosis in Locally Advanced Middle-Low Rectal Cancer After Neoadjuvant Chemoradiotherapy
    Zhuangbin Lin, Xiaobo Li, Jianyuan Song, Rong Zheng, Cheng Chen, Anchuan Li, Benhua Xu
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Breast Cancer Patients With Positive Apical or Infraclavicular/Ipsilateral Supraclavicular Lymph Nodes Should Be Excluded in the Application of the Lymph Node Ratio System
    Zhe Wang, Wei Chong, Huikun Zhang, Xiaoli Liu, Yawen Zhao, Zhifang Guo, Li Fu, Yongjie Ma, Feng Gu
    Frontiers in Cell and Developmental Biology.2022;[Epub]     CrossRef
  • Is Pathologic Axillary Staging Valid If Lymph Nodes Are Less than 10 with Axillary Lymph Node Dissection after Neoadjuvant Chemotherapy?
    Hee Jun Choi, Jai Min Ryu, Jun Ho Lee, Yoonju Bang, Jongwook Oh, Byung-Joo Chae, Seok Jin Nam, Seok Won Kim, Jeong Eon Lee, Se Kyung Lee, Jonghan Yu
    Journal of Clinical Medicine.2022; 11(21): 6564.     CrossRef
  • A novel nomogram for predicting locoregional recurrence risk in breast cancer patients treated with neoadjuvant chemotherapy and mastectomy
    Zhou Huang, Mei Shi, Wei-Hu Wang, Liang-Fang Shen, Yu Tang, Qing-Lin Rong, Li Zhu, Xiao-Bo Huang, Jian Tie, Jia-Yi Chen, Jun Zhang, Hong-Fen Wu, Jing Cheng, Min Liu, Chang-Ying Ma, Shu-Lian Wang, Ye-Xiong Li
    Radiotherapy and Oncology.2021; 161: 191.     CrossRef
  • Lymph node ratio as best prognostic factor in triple‐negative breast cancer patients with residual disease after neoadjuvant chemotherapy
    Gabriel A. De la Cruz‐Ku, Diego Chambergo‐Michilot, Bryan Valcarcel, Pamela Rebaza, Mecker Möller, Jhajaira M. Araujo, Daniel Enriquez, Zaida Morante, Cesar Razuri, Renato Luque, Antonella Saavedra, Eduardo Eyzaguirre, Maria Lujan, Naysha Noel, Joseph Pin
    The Breast Journal.2020; 26(9): 1659.     CrossRef
  • Development and validation of a nomogram incorporating axillary lymph node ratio to predict survival in node-positive breast cancer patients after neoadjuvant chemotherapy
    Jianguo Lai, Zihao Pan, Peixian Chen, Guolin Ye, Kai Chen, Fengxi Su
    Japanese Journal of Clinical Oncology.2019; 49(1): 22.     CrossRef
  • Lymph node ratio as an alternative to pN staging for predicting prognosis after neoadjuvant chemotherapy in breast cancer
    Dong Hui Cho, Soo Youn Bae, Ji Young You, Hong Kyu Kim, Young Woo Chang, Yoo Jin Choi, Sang Uk Woo, Gil Soo Son, Jae Bok Lee, Jeoung Won Bae, Seung Pil Jung
    The Kaohsiung Journal of Medical Sciences.2018; 34(6): 341.     CrossRef
  • Ganglio secundario como indicador de linfadenectomía axilar en pacientes afectas de cáncer de mama
    Manel Cremades, Mireia Torres, Montse Solà, Jordi Navinés, Icíar Pascual, Antonio Mariscal, Albert Caballero, Eva Castellà, Miguel Ángel Luna, Joan Francesc Julián
    Cirugía Española.2017; 95(9): 536.     CrossRef
  • Secondary Node Analysis as an Indicator for Axillary Lymphadenectomy in Breast Cancer Patients
    Manel Cremades, Mireia Torres, Montse Solà, Jordi Navinés, Icíar Pascual, Antonio Mariscal, Albert Caballero, Eva Castellà, Miguel Ángel Luna, Joan Francesc Julián
    Cirugía Española (English Edition).2017; 95(9): 536.     CrossRef
  • Risk factors of locoregional relapse in locally advanced breast cancer treated with neoadjuvant chemotherapy following mastectomy and radiotherapy
    Liang Huang, Sheng Chen, Wentao T. Yang, Zhiming Shao
    Oncotarget.2017; 8(24): 39703.     CrossRef
  • Lymph Node Ratio Analysis After Neoadjuvant Chemotherapy is Prognostic in Hormone Receptor-Positive and Triple-Negative Breast Cancer
    Jacqueline Tsai, Danielle Bertoni, Tina Hernandez-Boussard, Melinda L. Telli, Irene L. Wapnir
    Annals of Surgical Oncology.2016; 23(10): 3310.     CrossRef
  • Number of negative lymph nodes as a prognostic factor for ypN0-N1 breast cancer patients undergoing neoadjuvant chemotherapy
    Fei Xin, Yue Yu, Zheng-Jun Yang, Li-Kun Hou, Jie-Fei Mao, Li Xia, Xin Wang, Xu-Chen Cao
    Tumor Biology.2016; 37(6): 8445.     CrossRef
  • 12,234 View
  • 86 Download
  • 18 Web of Science
  • 14 Crossref
Close layer
Ovarian Ablation Using Goserelin Improves Survival of Premenopausal Patients with Stage II/III Hormone Receptor-Positive Breast Cancer without Chemotherapy-Induced Amenorrhea
Juan Zhou, San-Gang Wu, Jun-Jie Wang, Jia-Yuan Sun, Feng-Yan Li, Qin Lin, Huan-Xin Lin, Zhen-Yu He
Cancer Res Treat. 2015;47(1):55-63.   Published online August 21, 2014
DOI: https://doi.org/10.4143/crt.2013.165
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study was to assess the value of ovarian ablation using goserelin in premenopausal patients with stage II/III hormone receptor-positive breast cancer without chemotherapy-induced amenorrhea (CIA). Materials and Methods We retrospectively reviewed the data of breast patients treated between October 1999 and November 2007 without CIA. The Kaplan-Meier method was used for calculation of the survival rate. Log rank method and Cox regression analysis were used for univariate and multivariate prognostic analysis. Results The median follow-up period was 61 months. Initially, 353 patients remained without CIA after chemotherapy and 98 among those who received goserelin and tamoxifen (TAM). In univariate analysis, goserelin improved locoregional recurrence-free survival (LRFS) (98.9% vs. 94.1%, p=0.041), distant metastasis-free survival (DMFS) (85.4% vs. 71.9%, p=0.006), disease-free survival (DFS) (85.4% vs. 71.6%, p=0.005), and overall survival (OS) (93.5% vs. 83.5%, p=0.010). In multivariate analysis, goserelin treatment was an independent factor influencing DMFS (hazard ratio [HR], 1.603; 95% confidence interval [CI], 1.228 to 2.092; p=0.001), DFS (HR, 1.606; 95% CI, 1.231 to 2.096; p=0.001), and OS (HR, 3.311; 95% CI, 1.416 to 7.742; p=0.006). In addition, treatment with goserelin resulted in significantly improved LRFS (p=0.039), DMFS (p=0.043), DFS (p=0.036), and OS (p=0.010) in patients aged < 40 years. In patients aged ≥ 40 years, goserelin only improved DMFS (p=0.028) and DFS (p=0.027). Conclusion Ovarian ablation with goserelin plus TAM resulted in significantly improved therapeutic efficacy in premenopausal patients with stage II/III hormone receptor-positive breast cancer without CIA.

Citations

Citations to this article as recorded by  
  • An updated systematic review about various effects of microplastics on cancer: A pharmacological and in-silico based analysis
    Akmaral Baspakova, Afshin Zare, Roza Suleimenova, Aidar B. Berdygaliev, Bibigul Karimsakova, Kymbat Tussupkaliyeva, Nadiar M. Mussin, Kulyash R. Zhilisbayeva, Nader Tanideh, Amin Tamadon
    Molecular Aspects of Medicine.2025; 101: 101336.     CrossRef
  • Adjuvant ovarian function suppression and tamoxifen in premenopausal breast cancer patients: A meta-analysis
    Hamdy A. Azim, Kyrillus S. Shohdy, David F. Kaldas, Loay Kassem, Hatem A. Azim
    Current Problems in Cancer.2020; 44(6): 100592.     CrossRef
  • Feasibility and efficacy of ultrasonographic and laparoscopic guidance for microwave ablation of clinically normal canine ovaries
    Valentine D. Verpaalen, J. Brad Case, Michael J. Dark, S. Joel Cardenas-Goicoechea, Matt D. Winter, Sarah E. Boston, Fernando Garcia-Pereira, Alice S. Rhoton-Vlasak, Beau B. Toskich
    American Journal of Veterinary Research.2020; 81(9): 747.     CrossRef
  • Breast cancer in young patients. Peculiarities of prognosis and adjuvant hormone therapy (a literature review)
    D. N. Kravchenko, A. A. Parokonnaya, M. I. Nechushkin, E. A. Nikitina, N. D. Hakurinova
    Tumors of female reproductive system.2018; 14(3): 55.     CrossRef
  • Evaluating the Survival Benefit Following Ovarian Function Suppression in Premenopausal Patients with Hormone Receptor Positive Early Breast Cancer
    Lin Qiu, Fangmeng Fu, Meng Huang, Yuxiang Lin, Yazhen chen, Minyan Chen, Chuan Wang
    Scientific Reports.2016;[Epub]     CrossRef
  • Evaluation of a Survivorship Care Plan: Long-Term Use, Care Coordination and Quality of Life in Breast Cancer Survivors
    Meagan E Brennan, Frances M Boyle, Phyllis N Butow, Andrew J Spillane
    Breast Cancer Management.2015; 4(3): 145.     CrossRef
  • More Options for Fertility Preservation for Patients With Cancer
    Pamela N. Munster
    Journal of Clinical Oncology.2015; 33(22): 2413.     CrossRef
  • 13,067 View
  • 117 Download
  • 8 Web of Science
  • 7 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP